Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Freeport-McMoRan was one of the leading gainers on the S&P 500 on Monday after analysts at Cowen & Co boosted their price target on the stock....
...Shire was among Monday’s gainers as worries eased that the drugmaker had been caught up in the biotech sector’s mergers and acquisition frenzy....
...Smith & Nephew led Friday’s FTSE gainers, up 3.8 per cent to £10.65, on second-quarter sales and earnings that beat consensus estimates....
...Shares in Whitbread are among the best gainers on the index, up 3.5 per cent at £43.15 after strong sales numbers from its Costa Coffee cafés and Premier Inn chain of budget hotels....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Bernstein valued Pfizer’s consumer portfolio at about £9bn....
...Shares in Pfizer, which are up 3.4 per cent in the year to date, were 0.8 per cent lower to $22.38....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Among the gainers, Man Group rallied 3.4 per cent to 152½p as results this week prompted brokers including Merrill Lynch, Barclays Capital and UBS to raise their forecasts....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Pfizer rallied 1.4 per cent to $17.15, Merck rose 0.6 per cent to $38.30; Eli Lilly added 1 per cent to $36.54....
...Radioshack led S&P 500 gainers, adding 8.5 per cent to $23.65, after a report that it could be sold for $3bn to Best Buy, its bigger rival....
...Pfizer , the world’s largest pharmaceutical company, announced that it had halted trials of a new treatment for lung cancer....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Pfizer was a significant gainer rising 2.4 per cent to $14.26 after it was granted approval for Fablyn, the osteoporosis drug, from the European Commission....
...German pharmaceutical company Bayer rose 1.2 per cent to €53.34 on rumours of takeover interest from US rival Pfizer. Neither group has commented on the reports....
...Wednesday’s biggest gainers also fell. Monsanto , the agricultural group, retreated from its record high, dropping 3.2 per cent to $127.34....
...Bid talk helped Shire top the list of blue-chip gainers as stunned dealers digested news that the US bank Bear Stearns needed emergency funding....
...Scania was one of the day’s biggest gainers, up 5.0 per cent to SKr177.5. Investor AB rose 1.7 per cent to SKr176....
...Caterpillar , up 3.6 per cent at $78.48, led gainers in the Dow....
International Edition